Health Catalyst, Inc. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Health Catalyst, Inc. (HCAT)
CIK: 0001636422
Period of Report: 2021-12-02

Reporting Person: Llewelyn Linda (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-02	Common Stock	F	2839.00	$41.9475	Disposed	31709.00	Direct
2021-12-03	Common Stock	M	1100.00	$11.78	Acquired	32809.00	Direct
2021-12-03	Common Stock	M	1100.00	$10.80	Acquired	33909.00	Direct
2021-12-03	Common Stock	S	400.00	$39.2025	Disposed	33509.00	Direct
2021-12-03	Common Stock	S	500.00	$40.304	Disposed	33009.00	Direct
2021-12-03	Common Stock	S	200.00	$41.56	Disposed	32809.00	Direct
2021-12-03	Common Stock	S	1100.00	$42.87	Disposed	31709.00	Direct
2021-12-06	Common Stock	S	743.00	$37.6135	Disposed	30966.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-03	Stock Option (Right to Buy)	$11.78	M	1100.00	Disposed	2028-01-24	Common Stock (1100.00)	Direct
2021-12-03	Stock Option (Right to Buy)	$10.80	M	1100.00	Disposed	2028-09-27	Common Stock (1100.00)	Direct

Footnotes

F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2: Represents a weighted average price reported by the broker. These shares were sold as part of a block trade in multiple transactions at prices ranging from $40.33 to $42.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote with regard to the block trade.

F3: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 9, 2020, in accordance with Rule 10b5-1.

F4: Represents the weighted average sale price of the shares sold ranging from $38.90 to $39.74 per share, inclusive.

F5: Represents the weighted average sale price of the shares sold ranging from $40.05 to $40.62 per share, inclusive.

F6: Represents the weighted average sale price of the shares sold ranging from $41.53 to $41.59 per share, inclusive.

F7: Represents the weighted average sale price of the shares sold ranging from $37.45 to $38.17 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in Footnotes (4) - (7).

F8: 25% of the 17,954 shares underlying the options vested in an annual installment on January 24, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on January 24, 2022.

F9: 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.